Whereas numerous studies have examined the cardiac tissue content and secretion of atrial natriuretic peptide (ANP), the response of brain natriuretic peptide (BNP) in states of experimental cardiac overload is less well documented. Our recent partial cloning of the ovine BNP gene has enabled us to study changes in cardiac tissue concentration, together with tissue and circulating molecular forms of ANP and BNP, in response to cardiac overload induced by rapid ventricular pacing (n=7) and aortic coarctation (n=6). In normal sheep, although highest levels of BNP were found in atrial tissue (15-fold those of the ventricle), the BNP/ANP concentration ratio in the ventricles was 10-to 20-fold higher than the ratio calculated for atrial tissue. Compared with normal sheep, significant depletion of both ANP and BNP concentrations within the left ventricle occurred after rapid ventricular pacing. Size exclusion and reverse phase HPLC analysis of atrial and ventricular tissue extracts from normal and overloaded sheep showed a single peak of high molecular weight BNP consistent with the proBNP hormone. In contrast, immunoreactive BNP extracted from plasma drawn from the coronary sinus was all low molecular weight material. Further analysis of plasma BNP using ion exchange HPLC disclosed at least 3 distinct immunoreactive peaks consistent with ovine BNP forms 26-29 amino acid residues in length. These findings show that BNP is stored as the prohormone in sheep cardiac tissues and that complete processing to mature forms occurs at the time of secretion. The capacity to process the prohormone at secretion is not impaired by chronic heart failure.
Introduction
The discovery of atrial natriuretic peptide (ANP) and subsequent studies showing its production, storage and secretion from cardiac tissues in response to increased intracardiac pressure have established the heart as a bona fide endocrine organ with an important role in body fluid and blood pressure homeostasis (de Bold et al. 1981 , Espiner 1994 . In normal health ANP is synthesised and stored in atrial granules as a high molecular weight precursor (proANP1-126) (Miyata et al. 1985 , Yandle 1994 which is then enzymatically processed to a 'mature' (low molecular weight) circulating form (ANP99-126) at, or close to, the secretory event (Thibault et al. 1985 , Yandle et al. 1987 . A second natriuretic peptide, brain natriuretic peptide (BNP), originally isolated from porcine brain tissue extracts (Sudoh et al. 1988 ) is also a circulating hormone of cardiac origin , Nakao et al. 1990 ) with a similar range of biological actions to those of ANP (Espiner 1994) . However, in contrast to ANP, the secretion of which is regulated from atrial stores, BNP is less abundant in atrial granules (Hasegawa et al. 1991 , Nakamura et al. 1991 , Thibault et al. 1992 and is thought to be constitutively secreted, predominantly from the ventricles (Mukoyama et al. 1991 , Ogawa et al. 1991 . BNP is further distinguished from ANP by its species heterogeneity in amino acid sequence (Rosenweig & Seidman 1991) , variation in size of mature forms (Yandle 1994) and differences in proportions of high and low molecular weight forms both in cardiac tissue and plasma (Tamura et al. 1994) . These factors have restricted the development of specific assays for the hormone such that, compared with ANP, much less is known concerning changes in tissue and circulating BNP forms accompanying states of cardiac overload. In animal models of congestive heart failure (CHF), increases in plasma ANP chiefly comprise the low molecular weight form (ANP99-126), whereas in humans, larger forms including -ANP (an anti-parallel dimer of ANP) and proANP increase proportionately as severity of heart failure increases (Ando et al. 1990 ). Whether similar changes in BNP forms occur with demands from sustained increases in secretion is unclear. Our recent partial cloning of the ovine BNP gene (Aitken et al. 1994) , development of appropriate assays for ovine BNP (Yandle 1994 ) and the availability of suitable models to study cardiac overload (Fitzpatrick et al. 1989 , Charles et al. 1996 have enabled us to address these questions. We now report changes in cardiac tissue ANP and BNP concentrations and molecular forms, together with concomitant changes in plasma in two models of cardiac overload -congestive heart failure induced by rapid ventricular pacing and left ventricular hypertrophy induced by aortic banding.
Materials and Methods

Tissue sample collection and preparation
Three groups of sheep were studied -normal, sheep with pacing-induced heart failure (CHF) and sheep with left ventricular hypertrophy induced by aortic coarctation (AC). The study protocol was approved by the Christchurch School of Medicine Animal Ethics Committee. Normal cardiac tissue was collected (on ice) from age-and weight-matched sheep (n=13) from a local abattoir and stored at 80 C within 1 h of slaughter. Cardiac tissue from sheep with CHF (n=7) was obtained after 7 days of rapid right ventricular pacing. Under thiopentone anaesthesia (17 mg/kg body weight), a 7 French His bundle electrode pacing wire was advanced into the right ventricle via a jugular vein. Post surgery, sheep were paced at 225 beats per min and in all sheep CHF was evident by day 7, as indicated by laboured breathing, lethargy and loss of appetite, and confirmed post mortem by cardiomegaly, pulmonary oedema, bilateral pleural effusions and elevated natriuretic peptide levels in plasma. Post mortem heart tissue was collected on day 8 and stored at 80 C within 30 min of death. Cardiac tissue from sheep with AC (n=6) was obtained at the time of death (mean survival time 15 days post intervention). As previously reported (Charles et al. 1996) , suprarenal aortic coarctation induced intra ventricular hypertension (mean aortic pressure rises 50 mmHg above normal) and left ventricular hypertrophy (50% increase in left ventricular wall thickness). In all cases heart tissue was collected on ice at the time of death and stored at 80 C within 30 min.
Cardiac tissue extraction
Tissue sections comprising whole atria and a portion of the left and right ventricular free walls were thawed and diced on ice. Care was taken to prevent atrial contamination in the ventricular sections by excising sections half way down the chamber wall. Diced samples weighing approximately 1 g were gently boiled in 10 ml distilled water containing 10 µl Triton X-100 (Sigma, Penrose, Auckland, New Zealand) to remove intrinsic protease activity. After cooling on ice, glacial acetic (HAc) and 1  HCl were added to give final concentrations of 1  and 20 m respectively. Samples were homogenised at 4 C using an Ultra-Turrax T-25 dispersing homogeniser (IKA-Labortechnik, Staufen, Germany) at the highest speed possible for 3-5 min. The homogenate was centrifuged at 4 C for 25 min at 18 000 g. Supernatants were pipetted and stored at 80 C for future radioimmunoassay (RIA) and high performance liquid chromatography (HPLC). To assess extraction efficiency, recovery of peptide was estimated using three successive extractions performed on the same tissue sample. Three samples (each of normal atria and ventricle) were extracted as above, the supernatant pipetted off and the precipitate extracted a further two times. The concentration of ANP and BNP in all three supernatants was measured by RIA and recovery expressed as the percentage of total immunoreactivity (combined from three extractions) present in the first extract. Recoveries (mean of three separate studies) using this procedure were: 90% for ANP and BNP from atrium, 78% for ANP and 45% for BNP from the ventricle. Presented concentrations are adjusted accordingly.
Blood collection and preparation
Whole blood was collected from seven conscious sheep via a polyvinyl chloride catheter inserted into the coronary sinus and left atrium at the time of surgery, as previously described (Fitzpatrick et al. 1989) . 'Normal samples' represent collections taken from normal sheep prior to rapid ventricular pacing, whereas 'CHF samples' were drawn on day eight of continuous rapid ventricular pacing. To determine the effects of collection on exogenous and endogenous immunoreactive (ir) BNP, blood was collected into two groups of chilled 10 ml tubes containing 100 µl 15 mg/ml Na 3 -EDTA alone or 100 µl Na 3 -EDTA plus 1000 KIU/ml Trasylol (aprotinin; Bayer, Pymble, NSW, Australia). Group one tubes were also 'spiked' with 1600 pg synthetic porcine BNP26 (pBNP26). Samples were extracted as below for assay after incubation for 0, 0·5 and 2 h intervals at 4 C. No appreciable loss of exogenous or endogenous irBNP was seen in EDTA whole blood with or without Trasylol inhibitor. In order to assess possible degradation of immunoreactive forms during the SepPak extraction procedure, extracts of exogenous pBNP26 and pBNP32 were also run through ion exchange chromatography (IEHPLC) to verify the integrity of extracted BNP. After 2 h on ice no changes in immunoreactive forms were seen. Accordingly, all samples were subsequently collected into EDTA without Trasylol.
Plasma BNP and ANP extraction
Plasma BNP and ANP were extracted using Sep-Pak C 18 columns (Waters, Milford, MA, USA). Samples were passed through columns pre-equilibrated with absolute methanol and 4% HAc. The column was washed with 4% HAc and bound peptide eluted into glass tubes containing 10 µl 1% Triton X-100. Elution was achieved using ethanol:HAc:H 2 O in 80:4:20 ratio. The eluant was dried under a stream of air at 37 C and stored at 80 C. A portion of this extract was used to measure irBNP and ANP prior to HPLC analysis. Recovery of synthetic porcine BNP26 (which is identical to ovine BNP26 (Aitken et al. 1994) ) and ovine ANP99-126 from whole blood after centrifugation and SepPak extraction was 79 5% and 82 4% respectively (n=6). Presented values (pmol/l ...) are not adjusted for recovery.
Radioimmunoassay of natriuretic peptides
ANP ANP in tissue and plasma extracts was assayed as previously described (Yandle et al. 1991) .
BNP
Preparation of
125 I-porcine BNP Five micrograms pBNP26 (Peninsula, Belmont, CA, USA) and 18 megabecquerels (5 µl) Na[
125 I] (Amersham, Aylesbury, Bucks, UK) in 10 µl 0·5  phosphate buffer (pH 7·0) were reacted with 5 µl 2 mg/ml Chloramine T (Sigma) for 20-25 seconds, at room temperature. The reaction was stopped by adding 5 µl 10 mg/ml cysteine in phosphate buffer. Iodinated pBNP26 was purified using a 10 cm RP300 cartridge column (Brownlee Labs, Applied Biosystems, San Jose, CA, USA) equilibrated with 49 m potassium phosphate buffer (pH 2·9) and eluted with a gradient of 24-38% acetonitrile in phosphate buffer increasing over 20 min at 1 ml/min. The mono-iodinated peak was diluted with heat inactivated assay buffer (56 C, 30 min) and stored at 20 C.
Radioimmunoassay procedure
Antiserum to pBNP26 (RAS-9096N, Peninsula Laboratories) was diluted as per manufacturer's instructions (final dilution 1:50 000). Standards were prepared from synthetic pBNP26 (Bachem, La Jolla, CA, USA) taking the peptide purity data into account. Sample extracts, standards and antiserum solutions were all diluted in assay buffer, pH 7·4 (Yandle et al. 1987 ). The assay consisted of 100 µl standard (0-56 fmol/tube) pBNP26 or 100 µl sample incubated with 100 µl antiserum for 24 h at 4 C. Iodinated pBNP26 (100 µl, 10 000-15 000 c.p.m.) was added, vortexed and incubated for a further 24 h at 4 C. Free and bound tracer were separated by solid phase second antibody precipitation (Donkey Anti-Rabbit, Sac-Cell, Immunodiagnostics, Boulton, Tyne and Wear, UK) and the radioactive pellet counted in an LKB Gammamaster (LKB, Uppsala, Sweden). The assay had a mean zero binding of 35·8 0·7%, a detection limit of 0·52 0·04 fmol/tube (5 pmol/l) and an IC 50 (concentration displacing 50%) of 7·8 0·5 fmol/tube (78 pmol/l) over 20 assays. Nonspecific binding (assay buffer) was 2·5 0·1% and the blank assay value using distilled water was zero. A standard curve and parallel dilutions of ovine tissue and plasma extracts are shown in Fig. 1 . Supplied cross-reactivity data for the pBNP antiserum (Peninsula Laboratories) were: pBNP26, 100%; human ANP, <0·1%; rat BNP32, <0·001%; angiotensin, vasointestinal peptide, substance P and ANP (human) all 0%. In our hands, the antiserum gave the following cross-reactivities: human ANP and human BNP32, <0·04%; rat and human CNP22 and CNP53, 0·17% and 0·16% respectively. Within-assay coefficients of variation (C.V.) were 11% at 38 pmol/l (n=7), 5% at 244 pmol/l (n=8) and 11% at 19 pmol/l (n=7) on replicate extractions. Between-assay C.V. measured on repeated extracts of the same sample was 12% at 31 pmol/l in 13 assays over 3 months.
HPLC of ANP and BNP
HPLC analysis coupled with RIA was performed on extracts of tissue obtained from all three experimental groups as well as plasma extracts drawn from normal and heart failure sheep. HPLC was also performed on incubates of spiked and unspiked whole blood to assess Sep-Pak extraction integrity. Tissue and plasma extracts were loaded onto a G2000 SW size exclusion (SEHPLC) column (Toyosoda, Shinnanyo, Yamaguchi, Japan) and eluted with 20% acetonitrile (CH 3 CN)/0·1% trifluoroacetic acid (TFA) over 1 h at 0·5 ml/min. The eluate was collected in 0·5 ml fractions containing 10 µl 0·1% Triton X-100, dried under an air stream at 37 C and frozen at 80 C until dilution with assay buffer and RIA. Tissue extracts containing ANP and BNP immunoreactivity identified by SEHPLC were pooled, freezedried, reconstituted in HPLC solvent and subjected to reverse phase HPLC (RPHPLC) on a 22 cm Brownlee RP300 cartridge column equilibrated with 20% CH 3 CN/ 0·1% TFA at 40 C. Bound peptides were eluted with a gradient of CH 3 CN from 20% to 60% in 0·1% TFA over 40 min at 1 ml/min and aliquots diluted for RIA. The remaining fractions were frozen at 80 C for subsequent ion exchange HPLC.
Plasma BNP immunoreactivity identified by SEHPLC was further defined by weak cation ion-exchange (IEHPLC) chromatography using a 10 cm Brownlee CX-300 cartridge column (Applied Biosystems Inc., Foster City, CA, USA) at 40 C. Samples were loaded onto the column pre-equilibrated with a 90:10 mixture of solvent A (10 m ammonium formate in 30% isopropanol) and solvent B (1  ammonium formate in 30% isopropanol) at pH 6·6. Peptides were separated with a gradient of 90% A:10% B to 55% A:45% B over 55 min at 0·5 ml/min into fractions containing 10 µl 1·0% Triton X-100. These were frozen at 80 C and freeze-dried before dilution with assay buffer and RIA. All HPLC procedures were standardised using synthetic human (h)ANP99-126 and pBNP26 peptides (Bachem). Standard recoveries were: SEHPLC, 90% pBNP26 and hANP99-126; RPHPLC, 85% pBNP26, 90% hANP99-126; IEHPLC, 70-75% for pBNP26 and BNP32.
In order to characterise possible irBNP metabolites generated in vivo, plasma extracts from one sheep infused with synthetic pBNP26 (2 pmol/kg/min) for 30 min were analysed by IEHPLC. Samples drawn from the jugular vein at 30, 0, 25 and 30 min were extracted as described and assayed for irBNP after IEHPLC.
Statistics
Data are presented as the mean ... Statistics were performed on cardiac tissue and plasma levels using a two-tailed Student's t-test. Significance was defined as P<0·05. Table 1 , the concentration of ANP in the normal left atrium was approximately twice that of the right atrium (P=0·001). Left atrial levels tended to fall in CHF, and in AC sheep it was significantly reduced (P=0·039). Right atrial levels were unaffected by either intervention. ANP concentrations of the normal ventricles were 0·4% those of the atrium and there was no significant difference between right and left chambers. Ventricular concentrations tended to decrease in CHF, such that the level in the left ventricle was significantly lower than in normals (P=0·035). Average ventricular levels in CHF and AC sheep were, respectively, 0·2% and 0·3% those of the atrium.
Results
Cardiac tissue concentrations of ANP and BNP
ANP As shown in
BNP As in the case of atrial ANP, the left atrium concentration of BNP in normal sheep was significantly higher than the right atrium (P=0·029). Left atrial BNP concentration was unchanged in CHF, whereas the concentration in the right atrium was significantly increased (P=0·001). In contrast, in AC sheep right atrial concentration was significantly lower compared with normal (P=0·021) and CHF (P=0·007) animals (Table 1 ). In the normal ventricles, BNP concentrations were 6% those of the atrium, the left ventricle level again being significantly higher than the right (P=0·002). After interventions, ventricular levels were unchanged with the exception of the left ventricle in CHF which was significantly reduced (P=0·043). Ventricular concentrations in the CHF and AC groups were, respectively, 3% and 16% of those in the atrium.
BNP/ANP concentration ratios in cardiac tissue
The BNP/ANP concentration ratio in the normal right ventricle was 0·30 and in the left ventricle it was 0·67. These were 10-and 20-fold higher than their respective atrial ratios (both 0·03). Ratios in individual atria of stimulated animals were, for the most part, unchanged (CHF=0·05 and AC=0·03, both not significant). Ventricular ratios were not significantly raised in either CHF (right ventricle 0·50, left ventricle 0·86) or AC (right ventricle 0·80, left ventricle 2·16) groups compared with normal. However, in CHF tissue, the left ventricular BNP/ANP ratio was significantly higher than the right ventricular ratio (P=0·02).
Molecular forms of BNP and ANP in cardiac tissue
As shown in Fig. 2 , irBNP is a high molecular weight, monocomponent peptide in normal, CHF and AC atria analysed by SEHPLC and RPHPLC. Elution profiles of ventricular BNP were no different to those observed in atria. Immunoreactive ANP in normal and CHF tissue (Fig. 3) was also of high molecular weight and monocomponent in nature. Only the atrium of AC animals had altered ANP HPLC profiles -containing several forms which were seen in all HPLC profiles from this tissue (n=6). The major form co-eluted on SEHPLC with the immunoreactivity seen in normal and CHF tissues, while a second smaller peak eluted close to the column void volume, indicating a molecular weight greater than expected for the intact proANP hormone (Fig. 3c) . RPHPLC also revealed similar patterns for normal atria and ventricles but a slightly different profile for AC atria (Fig. 3f ) .
Plasma levels of ovine BNP and ANP
Plasma BNP and ANP levels were significantly raised in coronary sinus (CS) plasma of CHF sheep compared with normals (BNP (n=7): normal-CS 50 6 pmol/l vs CHF-CS 206 13 pmol/l, P<0·001; ANP (n=3): normal-CS 158 19 pmol/l vs CHF-CS 2069 384 pmol/l, P<0·01). Similarly, BNP and ANP levels in left atrial (LA) plasma were also significantly raised compared with normals (BNP (n=7): normal-LA 9 1 pmol/l vs CHF-LA 50 6 pmol/l, P<0·001; ANP (n=3): normal-LA 18 5 pmol/l vs CHF-LA 269 93 pmol/l, P<0·01). In normal sheep, plasma BNP and ANP levels in the CS were, respectively, fivefold and eightfold those in the LA. Similar ratios were present in CHF sheep (BNP fourfold, ANP eightfold).
Molecular forms of plasma BNP
As shown in Fig. 4 , all irBNP extracted from CS plasma (both in normal and CHF animals) is low molecular weight material as assessed by SEHPLC (Fig. 4, panels a  and b) . The elution position of irBNP on SEHPLC was consistent with pBNP26-or pBNP29-like forms, but not pBNP32. Left atrial plasma gave identical profiles. Similarly, irANP in plasma was predominately low molecular weight (data not shown). Further differentiation of irBNP using IEHPLC revealed three peaks of immunoreactivity (Fig. 4c ) in plasma drawn from normal sheep. Peak i eluted in a position consistent with synthetic pBNP26 standard, whereas peaks ii and iii eluted in positions intermediate between pBNP26 and pBNP32 standards. Plasma extracts from CHF sheep contained peaks i to iii and an additional peak (labelled iv, Fig. 4d ) when analysed by IEHPLC. Peak iv eluted 2 to 3 fractions earlier than peak ii and was present in all heart failure plasma tested (n=7). Relative heights of individual peaks (i-iv) varied among sheep. Only peak i was seen in IEHPLC profiles of plasma extracted from sheep receiving infusion of synthetic pBNP26 (data not shown). Since achieved plasma levels in the left atrium were approximately 20 pmol/l during infusion (and therefore equivalent with those seen in heart failure), it is unlikely that peaks ii to iv derive from metabolism of peptide constituting peak i.
Discussion
The current findings, derived from carefully programmed studies of induced cardiac overload in sheep, show that whereas cardiac tissue contains high molecular weight irBNP (presumably proBNP), only low molecular weight material is present in the circulation -even in the setting of profound heart failure. Surprisingly, when plasma extracts were further analysed using ion exchange HPLC, low molecular weight irBNP was seen to comprise at least 3-4 distinct forms, one of which appears to be unique to the setting of heart failure. Since these forms were present in coronary sinus plasma (and not found after infusion of exogenous pBNP26), they are likely to be products of the heart, rather than metabolites of a BNP26 form.
Current evidence indicates that BNP is predominately synthesised and secreted from the ventricle (Mukoyama et al. 1991 , Ogawa et al. 1991 , Kohno et al. 1992 . ANP is primarily secreted from the atria (Sugawara et al. 1985 , Ogawa et al. 1991 , Yoshimura et al. 1993 although secretion from ventricular myocytes has been shown (Irons et al. 1993) . Studies of BNP synthesis, storage and secretion in vivo have been restricted, largely because of the requirement for species-specific BNP assays and the need for suitable animal models to study the overloaded heart. Our recent partial cloning of the ovine BNP (and ANP) genes (Aitken et al. 1994 ) has enabled us to use the unique sequence homology between ovine and porcine BNP26 forms and develop suitable specific assays for their detection in plasma and tissue. The current RIA of ovine BNP shows adequate sensitivity and reliability, and has been fully validated to exclude artifacts resulting from collection, processing and extraction of both exogenous and endogenous ovine BNP forms. Our findings on cardiac tissue concentrations of ANP and BNP are similar to those reported in other species (Aburaya et al. 1989 , Mukoyama et al. 1991 , Rodeheffer et al. 1993 , Moe et al. 1996 . Further, in agreement with previous reports (Aburaya et al. 1989 , Tamura et al. 1994 we find in the normal heart that the atrial concentrations of ANP and BNP are, respectively, two and one orders of magnitude higher than ventricular concentrations. In CHF sheep no significant change in atrial ANP hormone levels occurred whereas a significant depletion of both ANP and BNP was found in tissue extracts of the left ventricle. Since hormone secretion is clearly enhanced (plasma levels of both ANP and BNP were greatly increased) it is possible that accelerated efflux of hormone occurs (associated with constitutive secretion) by depletion of a small pool of stored hormone within secretory vesicles. However, when the cardiac BNP/ANP ratio is considered, it is evident that differential changes in hormone stores occur in CHF. Whereas the BNP/ANP ratio within the atrium was not changed (0·03-0·05) by either intervention, the ratio in the left ventricle in CHF was increased, suggesting greater production of BNP by the left ventricle in this setting. The BNP/ANP ratio in both ventricles of AC sheep showed a tendency to increase (approximately threefold). Although this trend was not significant, it is consistent with the sustained increases in intra ventricular pressure and development of left ventricular hypertrophy previously described in these animals (Charles et al. 1996) . Similar observations have been made in spontaneously hypertensive rats developing malignant hypertension induced by deoxycorticosterone acetate (Kohno et al. 1992) . Taken together these findings provide further evidence that the mechanisms regulating BNP secretion differ from those of ANP.
HPLC analysis of cardiac tissue extracts shows that (like ANP) both atrial and ventricular tissue contain only high molecular weight BNP, eluting in a position consistent with the prohormone. From previous studies, it is clear that strong species variation in BNP forms occur in cardiac tissue extracts. Thus, in rats (Ogawa et al. 1991) and humans (Mukoyama et al. 1991) , low molecular weight forms predominate, contrasting with the pig , Marumo et al. 1992 ) and the hamster (Tamura et al. 1994) where irBNP is mostly high molecular weight. To our knowledge no previous studies have systematically examined cardiac tissue BNP forms before and after the induction of experimental heart failure. However, a recent report suggests that in rats, the ratio of low molecular weight/high molecular weight BNP (in both atrium and ventricle) is enhanced after myocardial infarction induced by coronary ligation (Sawada et al. 1997) . In the present study, neither of the two interventions (pacing-induced heart failure or cardiac overloading induced by aortic constriction) altered the molecular form of BNP in cardiac tissue suggesting that little, if any, proBNP is processed to low molecular weight forms prior to secretion. In rat and human atrial granules, irBNP is predominately low molecular weight, in contrast to irANP which is predominantly high molecular weight (Yandle 1994 ). Therefore, it is possible that in sheep proBNP is not directed to atrial storage granules at the trans-Golgi network. Recent studies in rats suggest that proANP aggregation into regulated secretory granules may depend on acidic Ca 2+ binding elements located within residues 11 to 44 of proANP, particularly Glu 23 -Glu 24 (Canaff et al. 1996) . Ovine proBNP lacks some acidic residues in this region (G D Aitken, personal communication) and is therefore unlikely to undergo Ca 2+ aggregation and subsequent processing before secretion. However, this does not explain the variation across species in the proportions of proBNP/ BNP found in cardiac tissue since all mammalian proBNP sequences reported so far lack the acidic (Ca 2+ binding element) amino acids at this putative site. Our findings of monocomponent high molecular weight BNP in cardiac tissue is similar to the findings reported in cardiomyopathic hamsters (Tamura et al. 1994) where, as in the normal hamster, cardiac tissue content appears to be monocomponent BNP. As found in other species (Miyata et al. 1985 , Sugawara et al. 1985 , Thibault et al. 1987 , our studies show that ANP in both atria and ventricle was also high molecular weight material both in normal sheep and after the induction of heart failure. However, additional peaks of immunoreactive ANP were noted on HPLC analysis of atrial extracts from AC sheep. Further work is required to assess the nature and significance of this finding and, in particular, to exclude artefacts from protein interactions in tissue extracts.
In striking contrast with the tissue extracts, sheep plasma contains only low molecular weight forms of BNP, even after the interventions inducing chronic heart failure. These findings suggest that processing is a late event, occurring at the time of secretion. Further, the findings indicate that the membrane capacity to process the prohormone to 'mature' BNP forms cannot be rate limiting in sheep. It is to be noted that in humans, proportionately more high molecular weight ANP appears in blood as heart failure worsens (Ando et al. 1990) , whereas in our experience, the ratio of high to low molecular weight BNP (2/1) in human heart failure is unaffected by severity (Yandle et al. 1993) . Presumably species differences in processing sites and efficiency underlie these findings. For example, recent reports show that cardiac gene expression of the processing enzyme furin is increased after myocardial infarction induced by coronary ligation in rats, and is associated with a concomitant fall in the ratio of high/low molecular weight BNP in cardiac tissues (Sawada et al. 1997) . In rats and humans, processing of proBNP appears to be less efficient than in sheep or hamsters with the genetically inbred disorder of cardiomyopathy (Tamura et al. 1994) . Further work on the precise enzyme(s) and its location and specificity of action is required to clarify these findings.
In contrast with ANP, where in health the 28 amino acid residue form appears in the circulation as the major component (Yandle 1994) , our data show that at least three distinct forms of low molecular weight BNP material are present in normal sheep plasma. Careful work to exclude artifact production during collection and extraction, and replication using multiple HPLC analyses has established their authenticity. The precise identity of these individual peaks awaits amino acid sequencing but this report presents strong evidence for the presence of at least a porcine BNP26 equivalent form. Since only one peak, co-eluting in the position of BNP26, was isolated from plasma drawn during exogenous infusion of pBNP26, it is unlikely that any of the other irBNP forms are metabolites of BNP26 itself. However, it is possible that BNP29-like forms may be present. Previous work has largely used SEHPLC and RPHPLC to determine the nature of BNP forms in plasma (Yandle et al. 1993) . The current work indicates that the separation of individual components may require ion exchange HPLC which in our hands has clearly revealed BNP forms not identified by either SEHPLC or RPHPLC. Interestingly, a study by Aburaya et al. (1989) , using ion exchange HPLC, identified three irBNP forms (BNP26, BNP29 and BNP32) in porcine plasma. In contrast to our findings, these multiple BNP forms were also present in cardiac tissue, suggesting that some proBNP processing occurs in this species. From the amino acid sequence now established for ovine proBNP (G D Aitken, personal communication) potential cleavage sites by furin (Arg-X-X-Lys/Arg) occur at Lys 73 and Arg 76 . Thus, our findings of putative BNP26-and BNP29-like forms in ovine plasma are consistent with the known site of enzyme action. There was no evidence in this study for a BNP32 form in ovine plasma. Furthermore, cleavage at residue Arg 70 (forming ovine BNP32) is unlikely as the Arg-X-XLys/Arg motif is not present upstream from this position. However, the nature of peak iv, (observed in heart failure plasma drawn from the coronary sinus), is uncertain and requires further study.
In conclusion, the BNP concentration in ovine heart tissues, although small in amount compared with ANP, is all high molecular weight material, consistent with proBNP. The finding of only low molecular weight BNP forms in the circulation, even in states of chronic cardiac overload, indicates a large capacity to process proBNP to mature forms late in the secretion pathway.
